JEA, FL's Issue 3 Series 6 Revenue Refunding Bonds Rated 'AA-' Jul 12

  • ID: 2177851
  • July 2012
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) July 6, 2012--Standard & Poor's Ratings Services has assigned its 'AA-' rating to JEA, Fla.'s proposed $123.04 million St. Johns River Power Park (SJRPP) revenue refunding bonds, issue 3 series 6. Bond proceeds will refund a portion of bonds outstanding. The outlook is stable. At the same time, Standard & Poor's affirmed its 'AA-' rating on JEA's senior-lien electric system revenue bonds, parity SJRPP bonds outstanding, and the Bulk Power Supply System (BPSS) bonds. JEA pays debt service on the SJRPP and BPSS bonds as operating expenses. Standard & Poor's also affirmed its 'A+' ratings on the subordinate-lien electric system revenue bonds. JEA budgets for gross debt service on its $268 million of electric system,...

Companies mentioned in this report are:

Action: Affirmed
Action: New Rating
Action: Outlook: Stable

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3


Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.